Linkozamidi: Razlika med redakcijama

Izbrisana vsebina Dodana vsebina
Marko Krmac (pogovor | prispevki)
Ustvarjeno s prevodom strani »Lincosamides«
 
Marko Krmac (pogovor | prispevki)
mBrez povzetka urejanja
Vrstica 1:
 
[[Slika:Lincomycin.png|sličica|Linkomicin]]
[[Slika:Clindamycin_skeletal.svg|sličica|Klindamicin.]]
'''Linkozamidi''' so skupina [[Antibiotik|antibiotikov]], ki vključuje [[Lincomycin|linkomicin]], [[Clindamycin|klindamicin]] in [[Pirlimycin|pirlimicin]].
 
== Struktura ==
Linkozamidi so sestavljeni iz enega [[PyrrolidinePirolidin|pirolidinskega]] obroča, vezanega na [[PyranosePiranoza|piranozno]] skupino (metiltio-linkozamid) preko amidne vezi.<ref name=":2">{{Navedi revijo|last=Rezanka|first=Tomas|last2=Spizek|first2=Jaroslav|last3=Sigler|first3=Karel|date=2007-04-01|title=Medicinal Use of Lincosamides and Microbial Resistance to Them|url=https://www.ingentaconnect.com/content/ben/aiamc/2007/00000006/00000002/art00005|journal=Anti-Infective Agents in Medicinal Chemistry|language=en|volume=6|issue=2|pages=133–144|doi=10.2174/187152107780361670|issn=1871-5214}}</ref><ref>{{Navedi splet|url=https://pubchem.ncbi.nlm.nih.gov/compound/56842237#section=Top|title=Lincosamides|last=Pubchem|website=pubchem.ncbi.nlm.nih.gov|language=en|accessdate=2018-09-19}}</ref> Hidroliza linkozamidov, posebej linkomicina, cepi molekulo na osnovno enoto sladkorja in prolina. Oba derivata se lahko znova združita v izvorno [[Učinkovina|zdravilno učinkovino]] ali njen derivat. <ref>{{Navedi splet|url=https://watermark.silverchair.com/16-suppl_A-13.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAlQwggJQBgkqhkiG9w0BBwagggJBMIICPQIBADCCAjYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMC2k7UGCdcMpdBRvVAgEQgIICB8oXffREEgeoMuBlPAvU1R0dEvdq50MSlro1FsiFqtpphpHiETISkLuDOjD1Qje687dlp9-gH7mf7bwh7KYuAIXeeZemeDgg9ecArJFWjMeV78HG24ysNgBFAnVmVbdHg2Y3Y3wdUY9-TsDq8suiXiyBTruSGdJLHoKfoPVt-OkaZpgv078jvOEfH2d_KtIMpIs-93z84STAuGmMqDUdpMubergBdWKELxpCG-hsx1iWC_iX2SncpLmKwofiIyna-kFhtjyFrHZAwio3ZO0STQ2B5pFun1_jEPR2J50KA477r9Gru7km8AlZlXFGxFMh8lF5B2xiu1LAY88fR4o1Vi-q3SLeusyvSyrjthZLFcoVhMEMhSY1RKRpnELlsGNZI_S8I8-Q5mDIUfNRhjlXKS0C2oPpX4G3WLRwTTigDDt6StSf_y_Cp_0RLCKj5V7juCR3iQnBBnWaQKTcUxd7qKLYUoZqL1ZS25wewBV3X_iDHmce0kn25ee91mH5D5qf28TinClIVpDdtyLN9mN8yPwhAxb6vf0dhN0KOQJjWUgxiFW-H4x9_83En10_0hqdQlCzDwrPFIIqURBrVmP0ix78NbhNEt-1TUnKY-eo2fGneBr4xrd82wmZv8mDZJyt7dsLVOcq5gym7FcbVmB5r6Hz4dSTC6IQgQF5DGLxa-fpmV_ldj1Ghg|title=Structure activity relationships in lincosamide and streptogramin antibiotics|last=Le Goffic|first=Francois|date=1985|website=Silverchair.com|archiveurl=|archivedate=|deadurl=|accessdate=}}</ref>
 
== Reference ==